Study details
Enrolling now
A Phase 2a Trial to Test a New Gel for Diabetic Foot Ulcers
Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.
NCT IDNCT06852976ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
60
Study length
about 10 months
Ages
18–75
Locations
1 site in NC
What this study is about
This trial is testing a new gel (MDI-1228-mesylate gel) compared with the usual treatment alone for people with diabetic foot ulcers. The goal is to see if the new gel helps heal the ulcers faster and reduces the size of the ulcers.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Standard of Care Alone
- 2.Take 0.75% MDI-1228_mesylate gel plus Standard of Care
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
inhaled
How treatment is administered
Treatment Assignment
Randomized (Open Label)
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug routes
inhaled
Endpoints
Primary: Drug related treatment emergent adverse events